Browsing by Author "Pushpendra Soni, Aleena, Alisha Bano, Samman, Asiya Fatima, Yasmeen Bano, Badruddeen"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Nanotechnology in Drug Delivery Systems
    (M/S Academic Publishers & Distributors/ZENODO, 2025) Pushpendra Soni, Aleena, Alisha Bano, Samman, Asiya Fatima, Yasmeen Bano, Badruddeen
    Nanotechnology has revolutionized drug delivery systems; now, therapeutic intervention can be targeted, efficient, and controlled. Traditional methods of administration of drugs often suffer from multiple disadvantages, such as poor bioavailability, non-specific distribution, and systemic toxicity. Nanocarriers such as nanoparticles, liposomes and dendrimers offer solutions to enhance the solubility and stability of drugs through selective targeting, thus improving the efficacy of drug therapy while reducing adverse effects. The main goals of nanotechnology-based drug delivery include optimizing the kinetic release of the drug, enhancing bioavailability, and allowing for sitespecific delivery. The delivery is facilitated through the exploitation of both passive and active targeting mechanisms, namely the Enhanced Permeability and Retention (EPR) effect and ligandmediated targeting, respectively. The strategies of controlled release, such as pH-sensitive, temperature-sensitive, enzyme-sensitive and redox-sensitive systems, enable the accurate delivery of drugs to diseased tissues while maintaining exposure as low as possible in the systemic circulation. Nanocarriers are promising in clinical applications, especially in cancer therapeutics, where they enhance the accumulation of drugs into the tumor. They reduce multidrug resistance and allow combination therapies. They permeate the blood-brain barrier in neurological disorders and improve drug delivery efficiency in conditions like Alzheimer’s and Parkinson’s disease. As such, they are emerging as promising tools for gene therapy, infectious disease management and regenerative medicine, too. Its large-scale production challenges the very issues of nanomedicine itself because of stability issues, regulatory aspects and eventual long-term toxicities. Future outlooks may include multifunctional and stimuli-responsive nanocarriers, self-assembling systems, and personalized medicine approaches tailored to the patient’s specific profile. Nanotechnology-driven perspectives ensure that nanotechnology will soon take over the future of drug delivery, especially in terms of effectiveness, precision and compliance with patients on treatment. Modern medicine will be completely transformed by innovative nanocarriers through new advancements in material science and bioengineering, making treatments safer and more effective in handling the disease.